Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'
Portfolio Pulse from Avi Kapoor
Jim Cramer shared his views on several companies on CNBC's 'Mad Money Lightning Round.' He described Marvell Technology's recent quarter as mixed and highlighted its partnership with TSMC. Cramer recommended Datadog, calling it a 'dynamite' company despite its high price. He labeled Centrus Energy as speculative and preferred the upcoming GE spinoff, Vernova. Cramer criticized Altimmune, suggesting Eli Lilly as a better option, and preferred RadNet over Lantheus Holdings. He expressed disappointment with SoFi Technologies due to its convertible bond issue and remained undecided on On Holding AG.
March 19, 2024 | 1:55 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Cramer described Centrus Energy as speculative and preferred the upcoming GE spinoff, Vernova.
Labeling Centrus Energy as speculative and preferring another entity suggests a negative short-term impact on LEU's stock.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70
NEGATIVE IMPACT
Cramer criticized SoFi Technologies for its convertible bond issue, which negatively impacted the stock.
The criticism of SoFi Technologies' convertible bond issue and its negative impact on the stock suggests a negative short-term impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 85
NEUTRAL IMPACT
Marvell Technology had a mixed quarter and expanded its partnership with TSMC.
The mixed quarter report and the significant partnership with TSMC suggest a neutral short-term impact, balancing potential concerns and optimism.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Cramer remained undecided on On Holding AG, describing its recent quarter as 'controversial.'
Cramer's indecision and the description of a 'controversial' quarter suggest a neutral short-term impact on On Holding's stock.
CONFIDENCE 70
IMPORTANCE 65
RELEVANCE 75
POSITIVE IMPACT
Cramer recommended buying Datadog, calling it a 'dynamite' company despite its high price.
Cramer's endorsement and the company's strong sales growth suggest a positive short-term impact on Datadog's stock.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
Cramer suggested Eli Lilly as a better option compared to Altimmune.
Cramer's preference for Eli Lilly over Altimmune, especially in the context of Altimmune's high-risk status, suggests a positive short-term impact for LLY.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 70